First Header Logo Second Header Logo

Connection

Steven Feldman to Cost-Benefit Analysis

Back to Details
This is a "connection" page, showing publications Steven Feldman has written about Cost-Benefit Analysis.
Steven Feldman
Connection Strength
3.118
Cost-Benefit Analysis
  1. Davis SA, Himmler S, Feldman SR. Cost-effectiveness analysis of using dermatologists versus pediatricians to treat mild to moderate acne. Dermatol Online J. 2017 May 15; 23(5).
    View in: PubMed
    Score: 0.551
  2. Feldman SR, Zhao Y, Gilloteau I, Graham CN, Miles L, McBride D, Herrera V. Higher Psoriasis Skin Clearance Is Associated with Lower Annual Indirect Costs in the United States: A Post Hoc Analysis from the CLEAR Study. J Manag Care Spec Pharm. 2018 Jul; 24(7):617-622.
    View in: PubMed
    Score: 0.149
  3. Vale SM, Hill D, Feldman SR. Pharmacoeconomic Considerations in Treating Actinic Keratosis: An Update. Pharmacoeconomics. 2017 02; 35(2):177-190.
    View in: PubMed
    Score: 0.135
  4. Taieb A, Stein Gold L, Feldman SR, Dansk V, Bertranou E. Cost-Effectiveness of Ivermectin 1% Cream in Adults with Papulopustular Rosacea in the United States. J Manag Care Spec Pharm. 2016 Jun; 22(6):654-65.
    View in: PubMed
    Score: 0.128
  5. James SM, Hill DE, Feldman SR. Costs of Common Psoriasis Medications, 2010-2014. J Drugs Dermatol. 2016 Mar; 15(3):305-8.
    View in: PubMed
    Score: 0.127
  6. Rouse NC, Farhangian ME, Wehausen B, Feldman SR. The cost-effectiveness of ustekinumab for moderate-to-severe psoriasis. Expert Rev Pharmacoecon Outcomes Res. 2015; 15(6):877-84.
    View in: PubMed
    Score: 0.124
  7. Feldman SR, Burudpakdee C, Gala S, Nanavaty M, Mallya UG. The economic burden of psoriasis: a systematic literature review. Expert Rev Pharmacoecon Outcomes Res. 2014 Oct; 14(5):685-705.
    View in: PubMed
    Score: 0.113
  8. Mauskopf J, Samuel M, McBride D, Mallya UG, Feldman SR. Treatment sequencing after failure of the first biologic in cost-effectiveness models of psoriasis: a systematic review of published models and clinical practice guidelines. Pharmacoeconomics. 2014 Apr; 32(4):395-409.
    View in: PubMed
    Score: 0.111
  9. Ahn CS, Gustafson CJ, Sandoval LF, Davis SA, Feldman SR. Cost effectiveness of biologic therapies for plaque psoriasis. Am J Clin Dermatol. 2013 Aug; 14(4):315-26.
    View in: PubMed
    Score: 0.106
  10. Yentzer BA, Gustafson CJ, Feldman SR. Explicit and implicit copayments for phototherapy: examining the cost of commuting. Dermatol Online J. 2013 Jun 15; 19(6):18563.
    View in: PubMed
    Score: 0.105
  11. Alikhan A, Daly M, Wu J, Balkrishnan R, Feldman SR. Cost-effectiveness of a hydroquinone/tretinoin/fluocinolone acetonide cream combination in treating melasma in the United States. J Dermatolog Treat. 2010 Sep; 21(5):276-81.
    View in: PubMed
    Score: 0.087
  12. Anis AH, Bansback N, Sizto S, Gupta SR, Willian MK, Feldman SR. Economic evaluation of biologic therapies for the treatment of moderate to severe psoriasis in the United States. J Dermatolog Treat. 2011 Apr; 22(2):65-74.
    View in: PubMed
    Score: 0.085
  13. Balkrishnan R, Bhosle MJ, Fleischer AB, Feldman SR. Prior authorization for topical psoriasis treatments: is it cost-beneficial for managed care? J Dermatolog Treat. 2010 May; 21(3):178-84.
    View in: PubMed
    Score: 0.085
  14. Balkrishnan R, Bhosle MJ, Camacho F, Fleischer AB, Feldman SR. Prescribing patterns for topical retinoids: analyses of 15 years of data from the national ambulatory medical care survey. J Dermatolog Treat. 2010 May; 21(3):193-200.
    View in: PubMed
    Score: 0.085
  15. Nolan BV, Yentzer BA, Feldman SR. A review of home phototherapy for psoriasis. Dermatol Online J. 2010 Feb 15; 16(2):1.
    View in: PubMed
    Score: 0.083
  16. Thomas K, Yelverton CB, Yentzer BA, Balkrishnan R, Fleischer AB, Feldman SR. The cost-effectiveness of rosacea treatments. J Dermatolog Treat. 2009; 20(2):72-5.
    View in: PubMed
    Score: 0.077
  17. Neidecker MV, Davis-Ajami ML, Balkrishnan R, Feldman SR. Pharmacoeconomic considerations in treating actinic keratosis. Pharmacoeconomics. 2009; 27(6):451-64.
    View in: PubMed
    Score: 0.077
  18. Feldman S, Pearce DJ, Williford PM. Surgical decision making for basal-cell carcinoma of the face. Lancet Oncol. 2008 Dec; 9(12):1119-20.
    View in: PubMed
    Score: 0.077
  19. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. Cost-effectiveness of biologic treatments for psoriasis based on subjective and objective efficacy measures assessed over a 12-week treatment period. J Am Acad Dermatol. 2008 Jan; 58(1):125-35.
    View in: PubMed
    Score: 0.071
  20. Steele T, Pawaskar M, Balkrishnan R, Fleischer A, Feldman SR. Does cost-effectiveness play a role in clinical trials? Dermatol Ther. 2007 Mar-Apr; 20(2):110-9.
    View in: PubMed
    Score: 0.068
  21. Miller DW, Feldman SR. Cost-effectiveness of moderate-to-severe psoriasis treatment. Expert Opin Pharmacother. 2006 Feb; 7(2):157-67.
    View in: PubMed
    Score: 0.063
  22. Yelverton CB, Kulkarni AS, Balkrishnan R, Feldman SR. Home ultraviolet B phototherapy: a cost-effective option for severe psoriasis. Manag Care Interface. 2006 Jan; 19(1):33-6, 39.
    View in: PubMed
    Score: 0.063
  23. Pearce DJ, Nelson AA, Fleischer AB, Balkrishnan R, Feldman SR. The cost-effectiveness and cost of treatment failures associated with systemic psoriasis therapies. J Dermatolog Treat. 2006; 17(1):29-37.
    View in: PubMed
    Score: 0.063
  24. Nelson AA, Pearce DJ, Fleischer AB, Balkrishnan R, Feldman SR. New treatments for psoriasis: which biologic is best? J Dermatolog Treat. 2006; 17(2):96-107.
    View in: PubMed
    Score: 0.063
  25. Simpson GL, Yelverton CB, Rittenberg S, Feldman SR. Do utilization management controls for phototherapy increase the prescription of biologics? J Dermatolog Treat. 2006; 17(6):359-61.
    View in: PubMed
    Score: 0.063
  26. Stein KR, Pearce DJ, Feldman SR. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care. Semin Cutan Med Surg. 2005 Mar; 24(1):52-7.
    View in: PubMed
    Score: 0.059
  27. Pearce DJ, Thomas CG, Fleischer AB, Feldman SR. The cost of psoriasis therapies: considerations for therapy selection. Dermatol Nurs. 2004 Oct; 16(5):421-8, 432.
    View in: PubMed
    Score: 0.057
  28. Parks L, Balkrishnan R, Hamel-Gariépy L, Feldman SR. The importance of skin disease as assessed by "willingness-to-pay". J Cutan Med Surg. 2003 Sep-Oct; 7(5):369-71.
    View in: PubMed
    Score: 0.054
  29. Wu JJ, Feldman SR, Rastogi S, Menges B, Lingohr-Smith M, Lin J. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States. J Dermatolog Treat. 2018 Dec; 29(8):769-774.
    View in: PubMed
    Score: 0.037
  30. Armstrong AW, Feldman SR, Korman NJ, Meng X, Guana A, Nyirady J, Herrera V, Zhao Y. Assessing the overall benefit of a medication: cumulative benefit of secukinumab over time in patients with moderate-to-severe plaque psoriasis. J Dermatolog Treat. 2017 May; 28(3):200-205.
    View in: PubMed
    Score: 0.033
  31. Lin HC, Lucas PT, Feldman SR, Balkrishnan R. Medication use and associated health care outcomes and costs for patients with psoriasis in the United States. J Dermatolog Treat. 2012 Jun; 23(3):196-202.
    View in: PubMed
    Score: 0.022
  32. Inglese MJ, Fleischer AB, Feldman SR, Balkrishnan R. The pharmacoeconomics of acne treatment: where are we heading? J Dermatolog Treat. 2008; 19(1):27-37.
    View in: PubMed
    Score: 0.018
  33. McCall BP, Horwitz IB, Feldman SR, Balkrishnan R. Incidence rates, costs, severity, and work-related factors of occupational dermatitis: a workers' compensation analysis of Oregon, 1990-1997. Arch Dermatol. 2005 Jun; 141(6):713-8.
    View in: PubMed
    Score: 0.015
  34. Marchetti A, Feldman SR, Kimball AB, Anderson RR, Miller LH, Martin J, An P. Treatments for mild-to-moderate recalcitrant plaque psoriasis: expected clinical and economic outcomes for first-line and second-line care. Dermatol Online J. 2005 Mar 01; 11(1):1.
    View in: PubMed
    Score: 0.015
  35. Duque MI, Jordan JR, Fleischer AB, Williford PM, Feldman SR, Teuschler H, Chen GJ. Frequency of seborrheic keratosis biopsies in the United States: a benchmark of skin lesion care quality and cost effectiveness. Dermatol Surg. 2003 Aug; 29(8):796-801; discussion 801.
    View in: PubMed
    Score: 0.013
  36. Dehkharghani S, Bible J, Chen JG, Feldman SR, Fleischer AB. The economic burden of skin disease in the United States. J Am Acad Dermatol. 2003 Apr; 48(4):592-9.
    View in: PubMed
    Score: 0.013
  37. Housman TS, Feldman SR, Williford PM, Fleischer AB, Goldman ND, Acostamadiedo JM, Chen GJ. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J Am Acad Dermatol. 2003 Mar; 48(3):425-9.
    View in: PubMed
    Score: 0.013
  38. Smith ES, Fleischer AB, Feldman SR, Williford PM. Characteristics of office-based physician visits for cutaneous fungal infections. an analysis of 1990 to 1994 National Ambulatory Medical Care Survey Data. Cutis. 2002 Mar; 69(3):191-8, 201-2.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.